Cara Therapeutics | CARA - Interest Expense On Debt


Cara Therapeutics reported -89.64M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Assertio Holdings USD 758K 1000 Jun/2024
Cara Therapeutics -89.64M 128.67M Dec/2025
Cassava Sciences USD 108.37M 396.06M Mar/2026
Chugai Pharma JPY 95M 260M Dec/2025
Cipla INR 131.3M 9M Mar/2026
Compugen USD 954K 116K Sep/2025
CSL USD 215M 111M Dec/2025
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 5.51M 597K Mar/2026
J&J USD 43M 25M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Pacira USD 3.7M 193K Mar/2026
Pfizer USD 671M 40M Mar/2026
RedHill Biopharma USD 89.8K 31.69M Jun/2024
Supernus Pharmaceuticals USD 910K 278K Jun/2023
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025